Andrews R Robbins Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Andrews R Robbins.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Andrews R Robbins. Andrews R Robbins is COO in ARRAY BIOPHARMA INC ($ARRY) and SVP, Commercial Operations in ARRAY BIOPHARMA INC ($ARRY) and President and CEO in Cogent Biosciences, Inc. ($UMRX) and Director in Harpoon Therapeutics, Inc. ($HARP).
Latest Insider Trading Transactions of Andrews R Robbins
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ARRY, COGT, HARP
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 07 2021 | HARP | Harpoon Therapeuti ... | Robbins Andrew R | Director | Option Exercise | A | 22.50 | 10,167 | 228,758 | 10,167 | |
| Feb 12 2021 | UMRX | Cogent Biosciences ... | Robbins Andrew R | President and CEO | Option Exercise | A | 10.17 | 315,200 | 3,205,584 | 315,200 | |
| Oct 27 2020 | UMRX | Cogent Biosciences ... | Robbins Andrew R | President and CEO | Option Exercise | A | 2.79 | 7,442,421 | 20,764,355 | 7,442,421 | |
| Apr 01 2020 | HARP | Harpoon Therapeuti ... | Robbins Andrew R | Director | Option Exercise | A | 11.78 | 20,335 | 239,546 | 20,335 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | D | 15.97 | 315,750 | 5,042,528 | 0 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | D | 10.92 | 335,250 | 3,660,930 | 0 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | D | 8.79 | 313,989 | 2,759,963 | 0 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | D | 3.00 | 236,250 | 708,750 | 0 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | D | 7.30 | 236,250 | 1,724,625 | 0 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | D | 8.20 | 12,500 | 102,500 | 0 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Sell | D | 0.00 | 130,542 | 0 | 0 | 130.5 K to 0 (-100.00 %) |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Sell | D | 48.00 | 71,022 | 3,409,056 | 130,542 | 201.6 K to 130.5 K (-35.24 %) |
| Apr 03 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 0.00 | 9,844 | 0 | 9,844 | |
| Apr 03 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 0.00 | 9,844 | 0 | 0 | |
| Apr 03 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Payment of Exercise | F | 24.60 | 8,660 | 213,036 | 71,022 | 79.7 K to 71 K (-10.87 %) |
| Apr 03 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 0.00 | 19,688 | 0 | 79,682 | 60 K to 79.7 K (+32.82 %) |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 4.63 | 87,500 | 405,125 | 0 | |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 8.20 | 37,500 | 307,500 | 12,500 | |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Sell | S | 20.03 | 239,626 | 4,798,511 | 59,994 | 299.6 K to 60 K (-79.98 %) |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 4.63 | 87,500 | 405,125 | 299,620 | 212.1 K to 299.6 K (+41.25 %) |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 8.20 | 37,500 | 307,500 | 212,120 | 174.6 K to 212.1 K (+21.48 %) |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 0.00 | 13,968 | 0 | 41,907 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 0.00 | 13,083 | 0 | 26,166 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | A | 15.97 | 315,750 | 5,042,528 | 315,750 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | A | 0.00 | 52,625 | 0 | 52,625 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Payment of Exercise | F | 15.97 | 11,898 | 190,011 | 174,620 | 186.5 K to 174.6 K (-6.38 %) |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 0.00 | 27,051 | 0 | 186,518 | 159.5 K to 186.5 K (+16.96 %) |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 0.00 | 32,068 | 0 | 0 | |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Sell | S | 17.74 | 17,964 | 318,681 | 159,467 | 177.4 K to 159.5 K (-10.12 %) |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Payment of Exercise | F | 18.50 | 14,104 | 260,924 | 177,431 | 191.5 K to 177.4 K (-7.36 %) |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 0.00 | 32,068 | 0 | 191,535 | 159.5 K to 191.5 K (+20.11 %) |
| Apr 03 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 0.00 | 9,844 | 0 | 19,688 | |
| Apr 03 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Payment of Exercise | F | 16.32 | 8,675 | 141,576 | 159,467 | 168.1 K to 159.5 K (-5.16 %) |
| Apr 03 2018 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 0.00 | 9,844 | 0 | 168,142 | 158.3 K to 168.1 K (+6.22 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 4.63 | 87,500 | 405,125 | 87,500 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 4.91 | 89,634 | 440,103 | 0 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 4.91 | 20,366 | 99,997 | 0 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 5.14 | 200,000 | 1,028,000 | 0 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | A | 10.92 | 335,250 | 3,660,930 | 335,250 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | A | 0.00 | 55,875 | 0 | 55,875 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 0.00 | 13,082 | 0 | 39,249 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Sell | S | 10.72 | 282,874 | 3,032,409 | 158,298 | 441.2 K to 158.3 K (-64.12 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 4.63 | 87,500 | 405,125 | 441,172 | 353.7 K to 441.2 K (+24.74 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 4.91 | 89,634 | 440,103 | 353,672 | 264 K to 353.7 K (+33.95 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 4.91 | 20,366 | 99,997 | 264,038 | 243.7 K to 264 K (+8.36 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 5.14 | 200,000 | 1,028,000 | 243,672 | 43.7 K to 243.7 K (+457.96 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Payment of Exercise | F | 10.92 | 6,094 | 66,546 | 43,672 | 49.8 K to 43.7 K (-12.25 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 0.00 | 13,082 | 0 | 49,766 | 36.7 K to 49.8 K (+35.66 %) |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | M | 0.00 | 9,843 | 0 | 29,532 | |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Payment of Exercise | F | 8.94 | 6,293 | 56,259 | 39,558 | 45.9 K to 39.6 K (-13.72 %) |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Buy | M | 0.00 | 9,843 | 0 | 45,851 | 36 K to 45.9 K (+27.34 %) |
| Dec 29 2016 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | A | 8.79 | 313,989 | 2,759,963 | 313,989 | |
| Dec 29 2016 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrew R | COO | Option Exercise | A | 0.00 | 52,331 | 0 | 52,331 | |
| Apr 05 2016 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | COO | Option Exercise | A | 3.00 | 236,250 | 708,750 | 236,250 | |
| Apr 05 2016 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | COO | Option Exercise | A | 0.00 | 39,375 | 0 | 39,375 | |
| Apr 05 2016 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | COO | Payment of Exercise | F | 3.00 | 3,367 | 10,101 | 36,008 | 39.4 K to 36 K (-8.55 %) |
| Apr 03 2015 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | SVP, Commercial Ope ... | Option Exercise | A | 7.30 | 236,250 | 1,724,625 | 236,250 | |
| Apr 03 2015 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | SVP, Commercial Ope ... | Option Exercise | A | 8.20 | 50,000 | 410,000 | 50,000 | |
| Apr 03 2015 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | SVP, Commercial Ope ... | Grant | A | 0.00 | 39,375 | 0 | 39,375 | 0 to 39.4 K |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | SVP, Commercial Ope ... | Option Exercise | M | 0.00 | 32,069 | 0 | 32,069 | |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | SVP, Commercial Ope ... | Sell | S | 8.25 | 21,576 | 178,002 | 0 | 21.6 K to 0 (-100.00 %) |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | SVP, Commercial Ope ... | Payment of Exercise | F | 7.96 | 10,493 | 83,524 | 21,576 | 32.1 K to 21.6 K (-32.72 %) |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | SVP, Commercial Ope ... | Buy | M | 7.96 | 32,069 | 255,269 | 32,069 | 0 to 32.1 K |
| Apr 03 2014 | ARRY | ARRAY BIOPHARMA IN ... | Robbins Andrews R | SVP, Commercial Ope ... | Option Exercise | A | 4.63 | 175,000 | 810,250 | 175,000 |
Page: 1